02/06/2026
Results of a pancreatic cancer clinical trial have just been presented at the 2026 American Society of Clinical Oncology’s annual meeting in Chicago. The RASolute 302 clinical trial investigated whether the drug, daraxonrasib can be effectively used as a treatment for late-stage pancreatic cancer.
Researchers reported that the treatment could effectively double life expectancy for some patients with advanced pancreatic cancer.
GCF Executive officer Liam Willis said of the findings..."The development of treatments targeting KRAS mutations (KRAS inhibitors) are some of the most exciting developments we have seen in pancreatic cancer for a long time"
"Tragically, around 85% of pancreatic cancer patients are diagnosed at an advanced stage, when curative treatments are not an option. These results suggest that daraxonrasib is able to keep the cancer under control for longer, giving patients priceless extra time with their loved ones."
Read more here: https://bit.ly/4fRDln1